2024. Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study. Headache Medicine. 15, 3 (Sep. 2024), 170–174. DOI:https://doi.org/10.48208/HeadacheMed.2024.34.